IP Library Granted Patent US 12,247,200
Granted Patent B2
US 12,247,200 · App. 17/181,947 · Granted Mar 11, 2025

Compositions and methods for generating massively parallel nucleic acid sequencing libraries

Inventors: Kevin D. Allen (Austin, TX); Kerry Gunning (Austin, TX)
Assignee: BIOO Scientific Corporation
C12N15/1093C12Q1/6876
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,200
App. No.
17/181,947
Granted
Mar 11, 2025
Kind
B2
Abstract

Oligonucleotide primers and methods of use in producing sequencing libraries are provided according to aspects of the present disclosure which include, from 5′ to 3′, a homopolymer-hybridizing region, and an anchor region comprising 5′-(λ) n N m -3′, wherein the homopolymer-hybridizing region is a contiguous sequence of 5 to 20 elements, wherein the elements are nucleotides or T m increasing nucleotide analogs, wherein at least 4 of the elements are T m increasing nucleotide analogs, wherein the homopolymer-hybridizing region hybridizes to a complementary homopolymer tract of a target nucleic acid, wherein the complementary homopolymer tract comprises a contiguous sequence of complementary elements, wherein X is any nucleotide or nucleotide analog with the proviso that λ is not a nucleotide or nucleotide analog complementary to a complementary element of the complementary homopolymer tract, and wherein N is any nucleotide or nucleotide analog.

Claims (13)

1. An oligonucleotide primer, comprising, from 5′ to 3′, a 5′ primer tag sequence (PTS) covalently bonded to a 5′ residue of a homopolymer-hybridizing region, wherein the PTS consists of a linker and/or one or more nucleic acid sequences useful in nucleic acid sequence manipulation selected from: a sequencing site, a PCR site, and a hybridization site; the homopolymer-hybridizing region, and an anchor region comprising 5′-(λ) n N m -3′, wherein the homopolymer-hybridizing region hybridizes to a complementary homopolymer tract of a target nucleic acid, wherein the complementary homopolymer tract comprises a contiguous sequence of complementary elements, wherein the homopolymer-hybridizing region, and the anchor region together have a sequence selected from the group consisting of: SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, and wherein λ is any nucleotide or nucleotide analog with the proviso that k is not a nucleotide or nucleotide analog complementary to a complementary element of the complementary homopolymer tract, and wherein N is any nucleotide or nucleotide analog.

2. An oligonucleotide primer set, comprising two or more oligonucleotide primers according to claim 1 .

3. The oligonucleotide primer set of claim 2 , wherein at least two of the two or more oligonucleotide primers have different anchor regions.

4. The oligonucleotide primer set of claim 2 , comprising at least 12 or more oligonucleotide primers for use where the complementary elements of the target nucleic acid are “A”, wherein the oligonucleotide primer set comprises at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-AA-3′, at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-AT-3′, at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-AC-3′, at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-AG-3′, at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-CA-3′, at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-CT-3′ at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-CC-3′, at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-CG-3′, at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-GA-3′, at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-GT-3′, at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-GC-3′, and at least one oligonucleotide primer where 5′-(λ) 1 N 1 -3′ is 5′-GG-3′.

5. The oligonucleotide primer set of claim 2 , wherein the oligonucleotide primers of the primer set are provided in an equimolar mixture.

6. A method of generating a sequencing library, comprising:

providing an oligonucleotide primer according to claim 1 ;

annealing the oligonucleotide primer or oligonucleotide primer set to target nucleic acid, the target nucleic acid comprising the complementary homopolymer tract having at least 5 to 20 contiguous complementary elements;

extending the oligonucleotide primer under extension reaction conditions, producing an extension product complementary to at least a portion of the target nucleic acid;

polymerizing a second strand of DNA complementary to the extension product, producing double-stranded nucleic acid; and

amplifying the double-stranded nucleic acid using amplification primers, producing amplicons, thereby introducing one or more primer-derived nucleic acids into the amplicons, the one or more primer-derived nucleic acids comprising at least a sequencing primer binding site sequence.

7. The method of claim 6 , wherein the target nucleic acid is RNA and extending the oligonucleotide primer or primers of the oligonucleotide primer set comprises reverse transcription using a reverse transcriptase to produce a complementary DNA (cDNA).

8. A kit, comprising an oligonucleotide according to claim 1 .

Assignments (2)
MERGER Recorded Jan 19, 2026
From: BIOO SCIENTIFIC CORPORATION
To: REVVITY HEALTH SCIENCES, INC.
Reel/Frame 073506/0008 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2021
From: ALLEN, KEVIN D; GUNNING, KERRY
To: BIOO SCIENTIFIC CORPORATION
Reel/Frame 055390/0584 →
Continuity (3)
Provisional Application 63018712 · May 1, 2020
Provisional Application 62979697 · Feb 21, 2020
Related Publication 20210261952A1 · Aug 26, 2021
References Cited (9)
US 9677130B2 · Wang et al. · 2017 [cited by applicant]
CA 2271256A1 · 1999 [cited by examiner]
Jacobsen et al., Direct Isolation of Poly(A)+ RNA from 4 M Guanidine Thiocyanate-Lysed Cell Extracts Using Locked Nucleic Acid-Oligo(T) Capture, 2004, Nucleic Acids Research, vol. 32, No. 7, 1-10 (Year: 2004). [cited by examiner]
Collins, J. et al., High-throughput and quantitative genome-wide messenger RNA sequencing for molecular phenotyping. BMC Genomics, Biomed Central, 16(1):578, Aug. 5, 2015, 13 pages. [cited by applicant]
Jacobsen, N. et al., Direct Isolation of Poly(A)+ RNA From 4 M Guanidine Thiocyanate-Lysed Cell Extracts Using Locked Nucleic Acid-Oligo(T) Capture, Nucleic Acids Research, Oxford University Press, GB, 32(7): E64, Apr. … [cited by applicant]
Jordan-Starck, T. et al., Mouse apolipoprotein J: Characterization of a gene implicated in atherosclerosis, Journal of Lipid Research, American Society for Biochemistry and Molecular Biology, Inc., US, 35(2): 194-210, F… [cited by applicant]
Perez-Perri, J. et al., Discovery of RNA-binding proteins and characterization of their dynamic responses by enhanced RNA interactome capture, Nature Communications, 9(1): 1-13, Dec. 1, 2018. [cited by applicant]
Zhang, B. et al., Allelic reprogramming of the histone modification H3K4me3 in early mammalian development, Nature, 537(7621): 553-557, Sep. 14, 2016. [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2021/019094 mailed Sep. 1, 2022, 8 pages. [cited by applicant]